All News

Managing your finances is not only important after graduating pharmacy school, but for years after when other factors come into play.

S. Diane Yamada, MD, president of the Society of Gynecologic Oncology (SGO), discusses the role of the pharmacist in gynecologic oncology patient care and treatment.

Best practices call for referring to resources, such as those from HHS and the University of Liverpool.

Cortizone-10 is used to treat a variety of skin conditions.

Pharmacy Times spoke to Seth DePasquale, RPh, BCSCP, senior director of hospital and health systems at Visante, about his session at the APhA 2022 Annual Meeting & Exposition, titled "Keeping Up with USP 800."

Shannon Hough, director of ClinReview and Clinical Content for McKesson, discusses the advantages of including pharmacy staff as part of the care team when payer or drug availability challenges arise.

Making the process to order a screening for hepatitis C virus easier improved screenings from 42% to approximately 80%.

Michele Belcher, president of the National Community Pharmacists Association, and pharmacist and pharmacy owner at Grants Pass Pharmacy, discusses ways of transforming the pharmacy profession’s current challenges into opportunities for positive change for the profession.

Encorafenib in combination With anti-EGFR monoclonal antibody improves overall survival.

Olaparib (Lynparza) was found to significantly improve overall survival in patients with germline BRCA-mutated, HER2-negative, high-risk early breast cancer.

Michael Abrams, MPH, PhD, senior health researcher at Public Citizen’s Health Research Group, discusses actions needed to help manage the opioid epidemic in the country.

S. Diane Yamada, MD, president of the Society of Gynecologic Oncology (SGO), discusses some key developments in the field of gynecologic oncology that will be on the agenda at the SGO 2022 annual meeting.

Phase 3 trial results also indicate that Alzheimer disease clinical decline was reduced in participants who had plasma p-tau181 reduction at 78 weeks.

Trial of empagliflozin (Jardiance) in adults with chronic kidney disease will end early based on a recommendation from the trial’s Independent Data Monitoring Committee based on clear positive efficacy.

Jeffrey B. Simon, JD, co-chair of the National Opioid Litigation Conference, discusses the historic settlement in a multi-district opioid lawsuit in Texas.

Explain to patients that research Is continually evolving and the need for booster shots does not mean the vaccinations do not work.

Patients treated with upadacitinib achieved clinical remission of ulcerative colitis more frequently through weeks 8 and 52 versus the placebo group.

Agency hopes green light for complex drug device combination improves competition and access more affordable medications.

Nucala is an IL-5 antagonist monoclonal antibody (immunoglobulin G1 kappa) for the add-on maintenance treatment of adult and pediatric patients with severe asthma and with an eosinophilic phenotype.

Zegerid is indicated for the treatment of frequent heartburn.

All patients present opportunities, but patients who might be considered more challenging due to their condition are often the cases where pharmacists might make the greatest difference

Patients may not admit or recognize when they have a brain injury, but pharmacists can be a valuable resource.

The medications may also help tackle the global problem of antibiotic resistance, investigators say.

Investigators call for routine monitoring of vaccination effectiveness as the pandemic continues to evolve.

Corium’s Adlarity system lowers the likelihood of adverse gastrointestinal (GI) events that are normally associated with the oral medication.

The KEYLYNK-010 trial was evaluating a combination of pembrolizumab (Keytruda) and olaparib (Lynparza) in patients with metastatic castration-resistant prostate cancer who progressed following chemotherapy and either abiraterone acetate (Zytiga) or enzalutamide (Xtandi).

This month's generic product news features lanreotide injections, glycopyrrolate oral solution, and vasopressin.

Pfizer Inc and BioNTech seek approval for an additional fourth booster dose of their COVID-19 vaccine for adults 65 years of age and older who received an initial booster of any of the authorized or approved COVID-19 vaccines.